Mode
Text Size
Log in / Sign up
Phase 4 Completed N=80 Randomized Triple-blind Treatment

Intrathecal Opioids for Colorectal Resection

Colorectal Surgery · Pain, Postoperative · Analgesic, Opioid
Source: ClinicalTrials.gov NCT04752033 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcomePrimary: Postoperative Pain Control — 4.5; 1.6; 1.75; 2.75 score on a scale
◆ Published Evidence
Emerging
2citations · ~2 / year
A Prospective Randomized Dose-Finding Study of Intrathecal Opioids for Postoperative Analgesia After Minimally Invasive Colorectal Operation.
Mayo Clinic proceedings. Innovations, quality & outcomes · 2025 · Open access · Likely link

Summary

This research study is being done to determine the optimal dose of spinal morphine and hydromorphone in patients undergoing minimally-invasive (i.e., surgery performed through small entry sites and using cameras) colorectal surgery.

Linked Publications

  • A Prospective Randomized Dose-Finding Study of Intrathecal Opioids for Postoperative Analgesia After Minimally Invasive Colorectal Operation.
    Mayo Clinic proceedings. Innovations, quality & outcomes · 2025 · 2 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Postoperative Pain Control
3; 2.2; 2.25; 3; 4.25; 7
SECONDARY
Postoperative Pain Control
3; 2.2; 2.25; 3; 4.25; 7
SECONDARY
Presence and Severity of Opioid-related Side Effects at Their Highest Doses
1; 2; 1; 3; 0; 1
SECONDARY
Overall Benefits of Analgesia Score (OBAS)
5.5; 4.8; 2.33; 3.5; 4.5; 3
SECONDARY
Quality of Recovery (QoR) 15 Score
114.5; 120.5; 108.5; 123.75; 106.25; 131

Eligibility Criteria

Inclusion Criteria

  • Adult patients with an American Society of Anesthesiologists (ASA) physiological status I-III.
  • Undergoing colorectal minimally invasive surgery (MIS).
  • Age between 18 and 75 years of age.
  • Body mass index (BMI) between 18.5 and 40.
  • Ability to understand and read English.

Exclusion Criteria

  • Not able or unwilling to sign consent.
  • Patients undergoing ileostomy closure.
  • Patients undergoing ambulatory surgery or anticipated to be discharged sooner than 24 hours after surgery
  • Patients with chronic pain, requiring daily opioid use at the time of surgery.
  • Patient intolerant or allergic to opioids, NSAIDs, or acetaminophen.
  • Patients requiring emergent surgery.
  • Any contraindication to neuraxial anesthesia (coagulopathy, localized infection at the site of injection, pre-existing spinal pathology, or peripheral neuropathy).
  • Any patients currently receiving any anticoagulation medication other than aspirin and who have not discontinued the medication per American Society of Regional Anesthesia anticoagulation guidelines22, and/or an abnormal INR.
  • Patients with hepatic or renal insufficiency in as much as the patient is not a candidate for acetaminophen or NSAIDs, respectively.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04752033) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search